March 28 BlogPost Image copy
VasoDynamics Sets-up Laboratory at Stevenage Bioscience Catalyst

Laboratory facilities initiated to optimise development of product pipeline for the prevention of cancer therapy induced side-effects

28th March 2024 VasoDynamics Ltd, the pharmaceutical company developing therapies for the prevention of the debilitating side-effects of cancer treatment, today announces the initiation of its new laboratory facility in the Stevenage Bioscience Catalyst, which will enable in-house 3D Bioprinting, modelling and drug screening for preclinical development to optimise and enrich the company’s product pipeline.

Ningfeng Fiona Li, CEO of VasoDynamics, said:

“With the promising clinical progression of our platform products, supported by follow-up funding from our existing shareholder Good Ventures Foundation, we are delighted to announce the set-up of our laboratory at the Stevenage Bioscience Catalyst. These facilities, in conjunction with the recent appointment of a Head of Pre-Clinical Research, will enable us to rapidly progress the development work on our pipeline programmes, particularly NG13 for the prevention of chemotherapy-induced alopecia.”

Stevenage Biocatalyst Centre

Stevenage Bioscience Catalyst was formed through a collaboration between the Department for Business, Energy and Industrial Strategy (BEIS), GlaxoSmithKline, Wellcome and Innovate UK. This has created a globally recognised cluster for therapeutic research and development that provides support for translation and commercialisation of innovative new medicines. VasoDynamics laboratory is located within the community lab which offers use of a broad range of essential equipment.

For enquiries, please contact:

Dr Ningfeng Fiona Li, CEO +44 7969132263
Gary Bower, COO +44 7960388412

Notes to Editors:

About VasoDynamics

VasoDynamics is a pharmaceutical development company based in Stevenage-London, UK. It is a clinical stage biopharma company with experienced and culture-diversified executives who have shared vision to improve the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, the company is developing a number of cost-effective medicines, all of which target the prevention of debilitating and often dose-limiting complications of cancer therapy, such as chemotherapy and radiotherapy induced mucositis, dermatitis, and hair-loss. We take great pride in our culture of scientific and development rigour, and our programmes are based on scientific finding and innovations from world-leading research bodies. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculatures developing a serials of pipeline products for various types of cancer patient cohorts, hence to achieve the most effective and patient friendly protections to prevent severe side-effects during various types of cancer treatments.